Electrogene therapy with p53 of murine sarcomas alone or combined with electrochemotherapy using cisplatin.
The aim of our study was to evaluate feasibility and therapeutic potential of electrogene therapy with p53 alone or combined with electrochemotherapy using cisplatin on two murine sarcomas with different p53 status. Antitumor effectiveness of three consecutive electrogene treatments with p53 was more effective in wild-type LPB tumors than mutated SA-1 tumors, resulting in 21.4% of tumor cures in LPB tumors and 12.5% in SA-1 tumors. Pretreatment of tumors with electrogene therapy with p53 enhanced chemosensitivity of both tumor models treated by electrochemotherapy with cisplatin. After only one application of this treatment combination in the LPB tumor model, specific tumor growth delay was prolonged in the combined treatment group compared to electrogene therapy with p53 or electrochemotherapy with cisplatin alone, whereas in SA-1 tumors this treatment combination resulted in 31.6% of cured animals. Results of our study show that electrogene therapy with p53 alone or combined with electrochemotherapy is feasible and effective treatment of tumors. The combination of electrogene therapy and electrochemotherapy after only one application resulted in complete regression of tumors.
Grosel
Alenka
A
Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Sersa
Gregor
G
Kranjc
Simona
S
Cemazar
Maja
M
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D053672:Electrochemotherapy / Q000379:methods*; D005240:Feasibility Studies; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D049452:Green Fluorescent Proteins / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation; D012513:Sarcoma, Experimental / Q000628:therapy*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D049452:Green Fluorescent Proteins; D002945:Cisplatin